Longitudinal Study of Serum Lipids and Liver Enzymes in Workers With Occupational Exposure to Ammonium Perfluorooctanoate

Objective: To examine the relationship between serum perfluorooctanoate (PFOA), a biomarker of ammonium perfluorooctanoate exposure, and lipids and liver enzymes. Methods: We conducted a longitudinal study on 454 workers and used mixed models to examine the relationship between serum PFOA and lipids and liver enzymes. Results: One part per million (ppm) increase in serum PFOA was associated with a 1.06 mg/dL increase in total cholesterol, but was not associated with changes in triglycerides or other lipoproteins, after adjusting for potential confounders. Serum PFOA was also associated with total bilirubin (0.008 mg/dL decline/ppm) and serum aspartate aminotransferase (0.35 units increase/ppm) but not with the other liver enzymes. Conclusions: These medical surveillance data collected on workers for up to 25 years contributes useful information on the effects of ammonium perfluorooctanoate exposure on human liver and lipid chemistry.

[1]  G. W. Jepson,et al.  Binding of perfluorooctanoic acid to rat and human plasma proteins. , 2003, Chemical research in toxicology.

[2]  N. Rifai,et al.  Current recommendations of the Adult Treatment Panel and the Children and Adolescents Treatment Panel of the National Cholesterol Education , 2004 .

[3]  C. Elcombe,et al.  Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[4]  Nader Rifai,et al.  Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. , 2002, Clinical chemistry.

[5]  F. Gilliland,et al.  Serum perfluorooctanoic acid and hepatic enzymes, lipoproteins, and cholesterol: a study of occupationally exposed men. , 1996, American journal of industrial medicine.

[6]  Jeffrey H Mandel,et al.  Perfluorooctanesulfonate and other fluorochemicals in the serum of American Red Cross adult blood donors. , 2003, Environmental health perspectives.

[7]  J. V. Vanden Heuvel,et al.  Tissue distribution, metabolism, and elimination of perfluorooctanoic acid in male and female rats. , 1991, Journal of biochemical toxicology.

[8]  Jeffrey H Mandel,et al.  Epidemiologic Assessment of Worker Serum Perfluorooctanesulfonate (PFOS) and Perfluorooctanoate (PFOA) Concentrations and Medical Surveillance Examinations , 2003, Journal of occupational and environmental medicine.

[9]  I. Ockene,et al.  Calculated low density lipoprotein cholesterol levels frequently underestimate directly measured low density lipoprotein cholesterol determinations in patients with serum triglyceride levels < or =4.52 mmol/l: an analysis comparing the LipiDirect magnetic LDL assay with the Friedewald calculation. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[10]  I. Jialal,et al.  A more valid measurement of low-density lipoprotein cholesterol in diabetic patients. , 1997, The American journal of medicine.

[11]  J. Mandel,et al.  PLASMA CHOLECYSTOKININ AND HEPATIC ENZYMES, CHOLESTEROL AND LIPOPROTEINS IN AMMONIUM PERFLUOROOCTANOATE PRODUCTION WORKERS , 2000, Drug and chemical toxicology.

[12]  F. Benoit,et al.  A pilot study on the determination of perfluorooctanesulfonate and other perfluorinated compounds in blood of Canadians. , 2004, Journal of environmental monitoring : JEM.

[13]  K P Lee,et al.  Biochemical and morphological studies of ammonium perfluorooctanoate-induced hepatomegaly and peroxisome proliferation. , 1987, Experimental and molecular pathology.

[14]  P. Wilson,et al.  Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. , 1990, Clinical chemistry.

[15]  K. Helzlsouer,et al.  Historical Comparison of Perfluorooctanesulfonate, Perfluorooctanoate, and Other Fluorochemicals in Human Blood , 2005, Environmental health perspectives.

[16]  F. Gilliland,et al.  An epidemiologic investigation of reproductive hormones in men with occupational exposure to perfluorooctanoic acid. , 1998, Journal of occupational and environmental medicine.

[17]  A. Branchi,et al.  Accuracy of Calculated Serum Low-Density Lipoprotein Cholesterol for the Assessment of Coronary Heart Disease Risk in NIDDM Patients , 1998, Diabetes Care.

[18]  M. A. Mohd,et al.  Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. , 2004, Environmental science & technology.

[19]  L. Shaw,et al.  Community Exposure to Perfluorooctanoate: Relationships Between Serum Levels and Certain Health Parameters , 2006, Journal of occupational and environmental medicine.

[20]  Kouji Harada,et al.  The Influence of Time, Sex and Geographic Factors on Levels of Perfluorooctane Sulfonate and Perfluorooctanoate in Human Serum over the Last 25 years , 2004, Journal of occupational health.

[21]  Roger G Perkins,et al.  The Toxicology of Perfluorooctanoate , 2004, Critical reviews in toxicology.

[22]  G. R. Warnick,et al.  Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. , 1990, Clinical chemistry.

[23]  Jeffrey H Mandel,et al.  Serum concentrations of perfluorooctanesulfonate and other fluorochemicals in an elderly population from Seattle, Washington. , 2004, Chemosphere.

[24]  O. Spydevold,et al.  The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid. , 1992, Biochimica et biophysica acta.

[25]  F. A. Ubel,et al.  Health status of plant workers exposed to fluorochemicals--a preliminary report. , 1980, American Industrial Hygiene Association journal.

[26]  G. Kennedy,et al.  Absorption, Distribution, and Excretion of Ammonium Perfluorooctanoate (APFO) After Oral Administration to Various Species , 2006, Drug and chemical toxicology.

[27]  Timothy R. Church,et al.  Quantitative Evaluation of Perfluorooctanesulfonate (PFOS) and Other Fluorochemicals in the Serum of Children , 2004 .

[28]  J. V. Vanden Heuvel,et al.  Lack of evidence for perfluorodecanoyl- or perfluorooctanoyl-coenzyme A formation in male and female rats. , 1992, Journal of biochemical toxicology.

[29]  Douglas R. Morgan,et al.  Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management , 1998 .

[30]  M. Sentí,et al.  Calculated Low-Density Lipoprotein Cholesterol Should Not Be Used for Management of Lipoprotein Abnormalities in Patients With Diabetes Mellitus , 1993, Diabetes Care.